Science Corp. Raises $230M, Preps Brain Sensor Trials
Get the Tech newsletter
Daily tech — startups, AI labs, chips, the launches that shape the next decade. Free.
- Science Corporation completed a $230 million Series C round last month, valuing the company at $1.5 billion.
- Dr. Murat Günel, chair of Yale Medical School’s Department of Neurosurgery, joined Science as a scientific adviser to lead its first U.S. human trials of the biohybrid brain‑computer interface.
- PRIMA, Science’s most advanced product, is a vision‑restoring implant for macular degeneration that the company plans to launch in Europe after regulatory approval, possibly as soon as this year.
- Science is developing a biohybrid sensor that embeds lab‑grown neurons capable of optical stimulation and designed to integrate naturally with a patient’s brain tissue.
- The sensor will be implanted inside the skull, resting on top of the cortex, and contains 520 recording electrodes roughly the size of a pea.
- The initial trial will enroll patients already undergoing craniectomy, such as stroke victims, to test safety and efficacy of the sensor without embedded neurons.
- Dr. Günel said it would be optimistic to expect human trials before 2027, indicating the technology remains early‑stage.
Why it matters: The $230 million infusion and the appointment of a top Yale neurosurgeon give Science a credible path to human testing, potentially accelerating the transition from animal prototypes to clinical applications and positioning the firm ahead of competitors like Neuralink in the emerging biohybrid BCI market.
